Oxycodone Myristate
Brand name: Xtampza Er
Rank #166 of 500 drugs by total cost
$96.1M
Total Cost
141,266
Total Claims
$96.1M
Total Cost
3,652
Prescribers
$680
Cost per Claim
17,578
Beneficiaries
141,311
30-Day Fills
$26K
Avg Cost/Provider
39
Avg Claims/Provider
About Oxycodone Myristate
Oxycodone Myristate (sold as Xtampza Er) was prescribed 141,266 times by 3,652 Medicare Part D providers in 2023, costing the program $96.1M. At $680 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 163 | Interferon Beta-1a (Avonex) | $98.3M | 11,314 |
| 164 | Guselkumab (Tremfya) | $97.1M | 7,102 |
| 165 | Levetiracetam (Levetiracetam) | $96.1M | 1,723,736 |
| 166 | Oxycodone Myristate (Xtampza Er) | $96.1M | 141,266 |
| 167 | Sevelamer Carbonate (Sevelamer Carbonate) | $95.6M | 277,192 |
| 168 | Aripiprazole Lauroxil (Aristada) | $93.3M | 31,120 |
| 169 | Trazodone Hcl (Trazodone Hcl) | $92.6M | 7,273,528 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology